JP2015509980A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509980A5 JP2015509980A5 JP2015500406A JP2015500406A JP2015509980A5 JP 2015509980 A5 JP2015509980 A5 JP 2015509980A5 JP 2015500406 A JP2015500406 A JP 2015500406A JP 2015500406 A JP2015500406 A JP 2015500406A JP 2015509980 A5 JP2015509980 A5 JP 2015509980A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- formula
- composition according
- compound
- interferon alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 108010047761 Interferon-alpha Proteins 0.000 claims 9
- 102000006992 Interferon-alpha Human genes 0.000 claims 9
- 241000711549 Hepacivirus C Species 0.000 claims 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 6
- 229960000329 ribavirin Drugs 0.000 claims 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 229950000038 interferon alfa Drugs 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/029011 WO2013137869A1 (en) | 2012-03-14 | 2012-03-14 | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509980A JP2015509980A (ja) | 2015-04-02 |
| JP2015509980A5 true JP2015509980A5 (enrdf_load_stackoverflow) | 2015-05-14 |
Family
ID=47844511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500406A Pending JP2015509980A (ja) | 2012-03-14 | 2012-03-14 | Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2015509980A (enrdf_load_stackoverflow) |
| WO (2) | WO2013137869A1 (enrdf_load_stackoverflow) |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質，その製造法および中間体 |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| WO1995013090A1 (en) | 1993-11-10 | 1995-05-18 | Enzon, Inc. | Improved interferon polymer conjugates |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US5767097A (en) | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DE602004010137T2 (de) | 2003-05-21 | 2008-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbindungen als hepatitis c inhibitoren |
| CA2554089C (en) | 2004-02-09 | 2013-10-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2005116054A1 (en) | 2004-05-25 | 2005-12-08 | Boehringer Ingelheim International, Gmbh | Process for preparing acyclic hcv protease inhibitors |
| NZ591013A (en) | 2008-09-16 | 2012-09-28 | Boehringer Ingelheim Int | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hepatitis c viral inhibitor |
| CA2737376A1 (en) | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| EP2358355B1 (en) | 2008-11-21 | 2013-11-06 | Boehringer Ingelheim International GmbH | Pharmaceutical composition of a potent hcv inhibitor for oral administration |
| CA2767692C (en) | 2009-07-07 | 2017-03-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
| PH12012500827A1 (en) | 2009-10-30 | 2013-01-07 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
-
2012
- 2012-03-14 JP JP2015500406A patent/JP2015509980A/ja active Pending
- 2012-03-14 WO PCT/US2012/029011 patent/WO2013137869A1/en active Application Filing
-
2013
- 2013-02-27 WO PCT/US2013/027916 patent/WO2013138064A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530874A5 (enrdf_load_stackoverflow) | ||
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| JP2015505565A5 (enrdf_load_stackoverflow) | ||
| JP2017057230A5 (enrdf_load_stackoverflow) | ||
| JP2004509061A5 (enrdf_load_stackoverflow) | ||
| NZ631155A (en) | Combination of two antivirals for treating hepatitis c | |
| JP2009504157A5 (enrdf_load_stackoverflow) | ||
| JP2013507439A5 (enrdf_load_stackoverflow) | ||
| JP2011225596A5 (enrdf_load_stackoverflow) | ||
| JP2019515908A5 (enrdf_load_stackoverflow) | ||
| JP2015517528A5 (enrdf_load_stackoverflow) | ||
| JP2018513188A5 (enrdf_load_stackoverflow) | ||
| RU2011127080A (ru) | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич | |
| JP2013518124A5 (enrdf_load_stackoverflow) | ||
| JP2011528333A5 (enrdf_load_stackoverflow) | ||
| RU2012136824A (ru) | Способы лечения вирусной инфекции гепатита с | |
| RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
| NZ598465A (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| JP2017514911A5 (enrdf_load_stackoverflow) | ||
| JP2002528502A5 (enrdf_load_stackoverflow) | ||
| CN102083435A (zh) | 特拉匹韦给药方案 | |
| Wedemeyer et al. | 96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study: 31 | |
| CA2525202A1 (en) | Use of alpha interferon, ribavirin, dsrna and neuraminidase inhibitors to treat avian influenza | |
| JP2007501806A5 (enrdf_load_stackoverflow) | ||
| RU2006101061A (ru) | Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела |